摘要
目的探讨眼动分析中凝视点数和反应性探索分析能否作为首发精神分裂症患者的诊断和治疗效果的客观依据以及这两种指标是否受不同抗精神病药物治疗的影响。方法将符合入组标准的53例精神分裂症患者随机分为氯丙嗪组24例、利培酮组29例进行治疗,疗程6w。随机抽取30例正常健康者为对照组,于患者组治疗前及治疗6w末测评三组眼动分析中凝视点数来分析其认知功能的改善情况。结果氯丙嗪组、利培酮组眼动分析中凝视点数评分均显著低于对照组(P<0.01),治疗6w末凝视点数评分虽有显著升高(P<0.01),但仍均显著低于对照组,差异均有极显著性(P<0.01)。结论凝视点数测评可作为首发精神分裂症患者诊断和判定疗效的客观依据,并且可能受药物的影响。
Objective To explore whether the NEF and RSS in exploratory eye movement could be regarded as objective evidences for diagnosis and curative effects of the first-episode schizophrenics and be influenced by different antipsychotics. Methods 53 schizophrenics fitting recruitment criteria were randomly divided into chlorpromazine（n=24） and risperidone（n=29） group for 6 weeks,randomly selected 30 normal healthy persons were as control group. The NEF was measured to analyze the improvements of cognitive function before treatment and at the end of the 6th week treatment. Results NEF scores of both chlorpromazine and risperidone groups were significantly lowere than those of control group（P〈0. 01） ;at the end of the 6th week although those increased significantly（P〈0.01） ,yet were lower compared with control group,difference was very significant（P〈0. 01）. Conclusion NEF measurements may be regarded as objective evidences for diagnosis and deciding curative effects and are possibly influenced by drugs;supplementary target and therapentic efficacy to the first-episode schizophrenia. And that they are maybe influenced by drugs treatment. Meanwhile, the research show that Risperidone group is no more than chlorpromazine group in improving cognitive function of the firstepisode schizophrenia.
出处
《临床心身疾病杂志》
CAS
2007年第6期487-489,共3页
Journal of Clinical Psychosomatic Diseases
关键词
首发精神分裂症
NEF
利培酮
氯丙嗪
First-episode schizophrenia
NEF
risperidone
chlorpromazine
